China’s NMPA Revises 2025 Regulations for Narcotic And Psychotropic Drug Research

China’s NMPA has issued the Provisions on Experimental Research of Narcotic Drugs and Psychotropic Substances, effective May 30, 2025. This new framework replaces the 2005 version and introduces stricter safety management requirements, clearer responsibilities for approval holders, and extended approval validity to enhance oversight and prevent diversion of controlled substances.

Overview of the Revision

The updated regulation, Announcement No. 51 of 2025, was issued under the authority of the Drug Administration Law, the Anti-Narcotics Law, and the Regulations on the Administration of Narcotic Drugs and Psychotropic Substances. It applies to preclinical research conducted for drug registration purposes involving controlled substances, including APIs, single and compound preparations, and plant-derived varieties.

Key Regulatory Enhancements

Safety and Oversight:
- Approval holders must implement comprehensive safety management systems.
- Active substances generated during research must be strictly controlled to prevent diversion.
- Third-party institutions may only conduct specialized, high-cost testing and must be supervised.
- Lead researchers must possess relevant professional qualifications to ensure scientific integrity and safety of the research process.
Approval Validity and Extension:
- Approval documents are valid for five years.
- Extensions are generally not permitted for non-innovative drugs.
- One-time extensions may be granted for innovative drugs based on research progress.
Management of Substances with Dependence Potential:
- Substances not yet listed but showing dependence potential, based on literature, international control status, structural similarity, or animal studies, must undergo technical review and may require formal approval.
Production Qualification Requirements:
- Controlled substances are tiered: Narcotics > Class I Psychotropics > Class II Psychotropics.
- At least one applicant or joint R&D unit must hold production qualifications for the same or higher category.
Role Clarification:
- Joint R&D Units: Co-applicants conducting research; changes require NMPA approval.
- Third-Party Institutions: Limited to specialized testing and cannot subcontract.

Policy Adjustments & Optimizations

Approval Validity: Extended to 5 years. Non-innovative drugs are generally not eligible for extensions.
Registration Requirement: Approval holders must submit registration applications (e.g., clinical trials, bioequivalence) within the validity period to avoid dormant approvals.
Dynamic Oversight: If dependence potential is discovered during trials or a substance is newly listed, a supplemental research application is required.

Implementation & Transition

The regulation is effective immediately. Existing approval holders may apply for extensions based on research progress. All stakeholders must comply with the updated provisions.

Impact on Overseas Manufacturers

Partnership Requirements: Foreign manufacturers must collaborate with Chinese entities holding appropriate production qualifications. Non-compliant partnerships will be rejected.
Retroactive Applications: If a substance is newly listed in China’s controlled catalog, overseas manufacturers must reapply for research approval to avoid penalties or suspension.
Outsourcing Restrictions: Core research activities (e.g., synthesis, formulation) cannot be outsourced. Only specialized testing may be permitted to delegate to qualified third parties.
Supply Chain Compliance: Approval holders must implement dual standards (GMP + controlled substance regulations) for managing intermediates and byproducts.

Strategic Outlook

The revised regulations raise compliance thresholds, restrict R&D partnerships, and tighten supply chain controls for overseas manufacturers. While short-term costs may increase, the long-term benefits include a more predictable and secure research environment. Multinational pharmaceutical companies with strong technical capabilities and localized strategies are well-positioned to thrive under this structured framework.

Further Information

Read the official announcement on the revised Provisions for Experimental Research of Narcotic Drugs and Psychotropic Substances (2025) from the National Medical Products Administration (NMPA) , please click here.

Have questions about compliance or collaboration opportunities for narcotic and psychotropic drug research in China? Contact Cisema for expert guidance.